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GENERAL COMMENTS
In this population-based investigation of reoperations after lumpectomy, the authors' objectives were "to investigate betweenhospital variation in the probability of reoperation within 90 days of initial breast conserving surgery (BCS), and the contribution of health systemlevel and other factors." Utilizing an administrative database, they identified an aggregate reoperation rate (ROR) of 29.1% in 34,458 women undergoing breast conserving surgery (BCS).
In half of women with receipt of reoperation, mastectomy was the final operation. Using advanced analytics, the authors identified significant variability of ROR at the individual hospital level. Additionally, after adjustment for patient-, year, and area-level socioeconomic status, they identified other independent variables that were associated with ROR. These were non-metropolitan location, surgery at low-volume Hospitals, East Asian ethnicity, in-situ disease and younger age.
The author's objectives are clear, their analysis was rigorous, and their results clearly answer their primary objective; there is very significant variation between hospitals. Thus, the author's findings are consistent with the existing literature, which identifies variability at the individual surgeon and hospital and region levels.
The strengths of this study are that it is population-based, has a large sample size and was investigated with advanced analytics. Also, the authors emphasize the downstream consequences of mastectomy in patients who initially wanted BCS. Multiple past articles don't report or don't emphasize this very significant departure from the patient's initially preferred type of treatment. As such, patients undergoing BCS need to be informed about possible later mastectomy and the reasons why. Another strength is that patients who underwent reoperation up to 90 days were included; many publications only include reoperations up to 30 or 60 days. The author's longer time-period to search for the receipt of reoperation ought to reflect a more accurate rate, especially since genetic testing, plastic surgery consultation, and post-lumpectomy MRI in patients with a positive margin or new identification of multifocal disease all delay time to reoperation.
The weaknesses of this study include the usual limitations always discussed with administrative/claims/billing data. Administrative data almost always lacks some patient, tumor, treatment and other characteristics that have been demonstrated in past studies to be associated with ROR. This is especially true for tumor size and nodal status. The authors acknowledged this limitation. Tumor grade, hormone receptor and HER-2 status are also associated with ROR, but not as strongly as tumor size. Without these variables, then the accuracy of "risk-adjusted" comparisons of ROR between hospitals is lessened, although I doubt it would have changed the final conclusion of this study which demonstrated significant variation. On the other hand, for best "fairness", future performance improvement efforts to reduce variability at the individual surgeon and hospital level should consider including at least tumor size and nodal status.
Another weakness was the inability of diagnostic codes to "distinguish excisional biopsies performed for diagnostic purposes from those performed with the intention of complete excision." Thus the authors were not able to control for this in their analyses. Multiple prior studies of BCS ROR exclude those patients who underwent "excisional biopsy", without intent to do a formal lumpectomy, because they have a higher chance of positive margins.
I believe this investigation is a significant contribution to the literature. Aggregate ROR of nearly 30% certainly warrant future initiatives to improve. The authors study also further motivates nations and healthcare systems to reduce unwanted variability.
I recommend the authors modify some of their "concluding" statements to better reflect the complexity of efforts to improve care in any sub-specialty area of medicine by the means of "regionalization of care", which the authors suggest.
Specifically, I recommend modification of these statements: 1) " Improvement over time provides ongoing support for policy initiatives aimed at regionalization." I find no convincing data in this paper to support a strong relationship between a very modest change in ROR over time with the argument for regionalization".
2) the last paragraph of manuscript statements:
"The association of BCS surgical volume and non-metropolitan location with mastectomy after BCS highlights the potential role of access to multidisciplinary, specialist breast cancer care in reducing unwarranted clinical variation." This is one strategy. I recommend it be balanced by other strategies and considerations.
3) "Disparities appear to have reduced, suggesting efforts to promote regionalisation of breast cancer care over the past decade may have had some success.49 50" See below. I recommend a brief discussion that includes the concept of regionalization but also includes the complexity of performance improvement that goes beyond the idea of regionalization.
Regionalization of care to improve care is sometimes necessary. But there are risks and there are alternatives to this strategy. Thus I recommend the nuances of many prior arguments for and against a regional strategy be acknowledged, even if briefly. The risks include alienation of non-specialty surgeons, rural surgeons and their systems. Some of these providers may have low ROR, despite lower volume practices and some higher volume surgeons have high ROR, as evidenced in publications that queried the American Society of Breast Surgeons patient registry. Would it be fair to promote a system that encourages patients to avoid a "good" performer because of their rural location or lower volume? Also, an argument by "specialists" to encourage regionalization may miss the patient perspective. Of course all patients want "good" care, but most patients prefer local care for many reasons, not limited to transportation/hotel/traveling costs and life-scheduling efficiency. And they often have trust in their local providers. For sure, patients who prefer an onco-plastic lumpectomy, ought to have access to a surgeon specifically trained and experience for this, but not all patients need or want an onco-plastic reconstruction. And an alternative strategy to regionalization as the methodology to lower ROR is to develop mentorship, coaching, educational and other initiatives to improve care locally.
Jeffrey Landercasper
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Using multilevel models with cross-classified random effects for hospital and geographic area, the Authors investigate factors associated with reoperation within 90 days. The paper is reasonably well-written and easy to follow. I think the Introduction sets the paper into context and explains why it is needed in a good manner.
Comments to authors:
Abstract: This may be due to the required format of the Journal, but the contents of the section "Primary outcome measures" does not fit with the title. The contents include more on the methods than the outcome measures. Perhaps mentioning multilevel models is not needed here?
p.5, first line: Why defining BCS from procedure codes, not ICD-10 principal diagnosis?
p.8 and p.9: Should not proportion/probability of reoperation equal the sum of proportion/probability of undergoing mastectomy and reexcision? p.9, first paragraph: "Significant variation was also observed between residential SLAs, though this was notably smaller than the variation seen between hospitals". From Online Resource 4, the significant variation does not apply to the total reoperation probability, right?
Discussion of tumor characteristics limitations, p.12: Here you state that it is unlikely that the lack of information on these factors would account for the observed hospital variation in reoperation probability. However, on p.13 you state that "Women in remote areas of Australia are less likely to have undergone preoperative diagnosis by fine-needle aspiration or core biopsy, and instead, more likely to have undergone surgical biopsy; this may be exacerbated by lower rates of mammographic screening and referral for preoperative diagnosis". Does this not imply that the stage distribution may be skewed towards more higher stage tumors in the low-volume/nonmetropolitan hospitals, in turn giving higher reoperation rates? A simple way to shed some light on this, would be to compare the proportion of invasive cancers in data from all low-volume/nonmetropolitan hospitals to the high-volume hospitals.
Discussion of increased reoperation probabilities in low-volume or non-metropolitan hospitals, p.13: Are transfers between hospitals common when treating breast cancer patients in Australia? I think they could be in other countries. If they are, could not an alternative explanation of the negative effects of low-volume or nonmetropolitan hospitals be that patients receiving BCS at a lowvolume hospital are those that are too frail to be transferred and receive initial BCS at a higher-volume hospital? If this is not the case, some arguments why this is not a problem could be given in the Discussion. By the way, how is this handled in the definition of the outcome measures? Do you require the reoperation to be at the same hospital as the one performing the initial BCS or not? A sentence clarifying this when defining the reoperation outcome measures in Methods might also be worthwhile. Table aligns with the "Statistical analysis" at the bottom of p.6. There you write that "Baseline models included the random intercepts for hospital and SLA, and age-group at initial BCS, with subsequent models sequentially adding other patient-level sociodemographic and clinical variables, calendar year, area-level contextual and health system-level variables", and the sequential model building is clear from Online Resource 4. But from Table 2 , it seems like you have also run simple cross-tabulation analyses, or how do you arrive at the unadjusted estimates? And why are the adjusted probabilities only given in parentheses, hence putting most focus on the unadjusted estimates? A general comment to the Results section "Multilevel modelling" p.9, is that one really needs to confer with the Online Resource tables to get the details on which findings are significant or not, as only point estimates are presented in the proper paper tables. As such, the Online Resources are included more as a necessity in this part of the Results section, than as an add-on only needed for interested readers. This might be improved. And the interaction between calendar year and each of volume and location is not given in any table, does this mean it was not even included in the model building in Online Resource 4? That is, it was only included to produce Figure 3 (which incidentally only includes location, not volume)?
VERSION 1 -AUTHOR RESPONSE
Reviewer 1 (Jeffrey Landercasper)
Dr Landercasper highlights our clear objectives, rigorous methodology, and the consistency of our findings with the literature. He also acknowledges the study's strengths in that it is population-based, has allowed for a 90-day follow-up period, which better reflects the time period of reoperation, and that unlike the majority of the published literature, it emphasises later mastectomy as a significant departure from patients' initial BCS.
Dr Landercasper is satisfied with our acknowledgement of the limit ations of the use of administrative data (page 11), particularly the lack of detailed tumour information, but agrees that the addition of this information would not have changed the conclusions of the study regarding hospital variation. He points out, as have we (page 11), the inability to distinguish excisional biopsies performed for diagnostic purposes from those performed with the intention of complete excision. Unfortunately the ICD10 rubric for 'excision of lesion of breast' includes 'excisional biopsy '. As detailed in our methods (page 5), we took care to exclude open or incisional biopsies.
We agree with Dr Landercasper's suggestions to modify our concluding remarks about the regionalisation of care and herewith respond to his specific concerns: 1) "Improvement over time provides ongoing support for policy initiatives aimed at regionalization." I find no convincing data in this paper to support a strong relationship between a very modest change in ROR over time with the argument for regionalization". This statement appears in our Abstract and relates to the narrowing disparity in reoperation rates (particularly mastectomy) between metropolitan and non-metropolitan areas, and between low and high-volume hospitals, rather than the modest change in reoperation rates over time. We have modified our Abstract accordingly (see also page 2): 'Multilevel modelling suggests unwarranted clinical variation may be an issue, likely due to disparities in access to multidisciplinary breast cancer care and preoperative diagnostic procedures. However, the observed reduction in disparities over time is encouraging and indicates that guidelines and policy initiatives have the potential to improve regional breast cancer care."
2)
"The association of BCS surgical volume and non-metropolitan location with mastectomy after BCS highlights the potential role of access to multidisciplinary, specialist breast cancer care in reducing unwarranted clinical variation." This is one strategy. I recommend it be balanced by other strategies and considerations." AND 3)
"Disparities appear to have reduced, suggesting efforts to promote regionalisation of breast cancer care over the past decade may have had some success.49 50" See below. I recommend a brief discussion that includes the concept of regionalization but also includes the complexity of performance improvement that goes beyond the idea of regionalization. Regionalization of care to improve care is sometimes necessary. But there are risks and there are alternatives to this s trategy. Thus I recommend the nuances of many prior arguments for and against a regional strategy be acknowledged, even if briefly. The risks include alienation of non-specialty surgeons, rural surgeons and their systems. Some of these providers may have low ROR, despite lower volume practices and some higher volume surgeons have high ROR, as evidenced in publications that queried the American Society of Breast Surgeons patient registry. Would it be fair to promote a system that encourages patients to avoid a "good" performer because of their rural location or lower volume? Also, an argument by "specialists" to encourage regionalization may miss the patient perspective. Of course all patients want "good" care, but most patients prefer local care for many reasons, not limited to transportation/hotel/traveling costs and life-scheduling efficiency. And they often have trust in their local providers. For sure, patients who prefer an onco-plastic lumpectomy, ought to have access to a surgeon specifically trained and experience for this, but not all patients need or want an onco-plastic reconstruction. And an alternative strategy to regionalization as the methodology to lower ROR is to develop mentorship, coaching, educational and other initiatives to improve care locally."
We agree and have modified our Abstract (pages 1-2) and Discussion (pages 14-15) to incorporate these suggestions.
Reviewer 2 (Tron Anders Moger)
Prof Moger agrees the paper is well-written, that the Introduction sets it in context, and explains why it is needed. We herewith respond to his specific concerns:
-"Abstract: This may be due to the required format of the Journal, but the contents of the section "Primary outcome measures" does not fit with the title. The contents include more on the methods than the outcome measures. Perhaps mentioning multilevel models is not needed here?"
We have used the Abstract headings stipulated by the Journal; there is no heading for 'Methods' specifically, so we have followed the convention used by other papers in BMJ Open whereby the methods are incorporated under "Primary Outcome Measures".
-"p.5, first line: Why defining BCS from procedure codes, not ICD-10 principal diagnosis?"
As described in our Methods (page 4, paragraph 2; page 5, paragraph 1), our cohort was defined using both ICD-10 codes (to identify breast cancer patients) and ACHI procedure codes (to identify BCS). When used in combination, these codes have been shown to be reliable in identifying breast cancer patients undergoing BCS (see Discussion, page 11, paragraph 3).
-"p.8 and p.9: Should not proportion/probability of reoperation equal the sum of proportion/probability of undergoing mastectomy and re-excision?"
The difference is due to rounding; the proportions of patients who underwent re-excision, mastectomy and any reoperation are 14.93%, 14.14%, and 29.07% respectively.
-"p.9, first paragraph: "Significant variation was also observed between residential SLAs, though this was notably smaller than the variation seen between hospitals". From Online Resource 4, the significant variation does not apply to the total reoperation probability, right?" Correct; variation was seen for re-excision and mastectomy specifically. We have modified this sentence accordingly (page 9).
-"Discussion of tumor characteristics limitations, p.12: Here you state that it is unlikely that the lack of information on these factors would account for the observed hospital variation in reoperation probability. However, on p.13 you state that "Women in remote areas of Australia are less likely to have undergone preoperative diagnosis by fine-needle aspiration or core biopsy, and instead, more likely to have undergone surgical biopsy; this may be exacerbated by lower rates of mammographic screening and referral for preoperative diagnosis". Does this not imply that the stage distribution may be skewed towards more higher stage tumors in the low-volume/non-metropolitan hospitals, in turn giving higher reoperation rates? A simple way to shed some light on this, would be to compare the proportion of invasive cancers in data from all low-volume/non-metropolitan hospitals to the highvolume hospitals."
We appreciate this comment. Our Discussion provides a possible explanation for this variation: women who undergo BCS without preoperative diagnosis have a greater probability of reoperation. Women in remote parts of Australia are less likely to have undergone thorough preoperative diagnosis, particularly if diagnosed outside the setting of mammographic screening. It is possible that their tumours have been less-well characterised prior to surgery. Differences in diagnostic/referral/surgical pathways may have contributed to differences in reoperat ion rates for women in metropolitan and non-metropolitan areas.
Screening detects smaller tumours. Given that rates of screening are lower in women in remote areas, it is possible that they had larger tumours, and in turn, higher rates of reoperation; however, there is no solid evidence in available Australian data that this is the case (see for interest Roder et al. -"Discussion of increased reoperation probabilities in low-volume or non-metropolitan hospitals, p.13: Are transfers between hospitals common when treating breast cancer patients in Australia? I think they could be in other countries. If they are, could not an alternative explanation of the negative effects of low-volume or non-metropolitan hospitals be that patients receiving BCS at a low-volume hospital are those that are too frail to be transferred and receive initial BCS at a highervolume hospital? If this is not the case, some arguments why this is not a problem could be given in the Discussion. By the way, how is this handled in the definition of the outcome measures? Do you require the reoperation to be at the same hospital as the one performing the initial BCS or not? A sentence clarifying this when defining the reoperation outcome measures in Methods might also be worthwhile."
Thank you for these questions. We did not consider hospital transfers between the hospital in which the initial BCS was conducted and that of the reoperation; it was not necessary in this context, as the hospital in which the initial BCS was conducted was our primary interest (the 'exposure'). We have added a statement to this effect to the Methods (page 6).
We cannot assess the issue of frailty. It is possible that patients with comorbidities preferentially undergo treatment nearer to home (see for interest Craft et al. Variation in the management of early breast cancer in rural and metropolitan centres: implications for the organisation of rural cancer services. The Breast. 2010; 19:396-401) . However, in our dataset, there was no difference in the distribution of patients with comorbidities between metropolitan and non-metropolitan areas. Nor were the number of comorbidities found to be associated with reoperation in any of our analyses.
We feel that our use of a combination variable to capture both residential and hospital location adequately reflects 'movement' of patients for treatment.
-" Table 2 : I am not sure how well the information presented in the Table aligns with the "Statistical analysis" at the bottom of p.6. There you write that "Baseline models included the random intercepts for hospital and SLA, and age-group at initial BCS, with subsequent models sequentially adding other patient-level sociodemographic and clinical variables, calendar year, area-level contextual and health system-level variables", and the sequential model building is clear from Online Resource 4. But from Table 2 , it seems like you have also run simple cross -tabulation analyses, or how do you arrive at the unadjusted estimates? And why are the adjusted probabilities only given in parentheses, hence putting most focus on the unadjusted estimates?"
The results presented in Table 2 include both the unadjusted proportions and adjusted estimates based on multi-level modelling. We have switched the order such that the adjusted estimates are presented first, with the unadjusted proportions presented in parentheses.
-"A general comment to the Results section "Multilevel modelling" p.9, is that one really needs to confer with the Online Resource tables to get the details on which findings are significant or not, as only point estimates are presented in the proper paper tables. As such, the Online Resources are included more as a necessity in this part of the Results section, than as an add-on only needed for interested readers. This might be improved." Table 2 presents predicted probabilities; when performing multinomial multilevel modelling, predicted probabilities are preferred over odds ratios (see for interest Steele, F. (2013) Module 10: Single-Level and Multilevel Models for Nominal Response Concepts. LEMMA VLE, University of Bristol, Centre for Multilevel Modelling. https://www.cmm.bris.ac.uk/lemma/pluginfile.php/15197/mod_resource/cont ent/2/Module%2010_multi nomial_MLwiN_practical_final. pdf ). However, selected odds ratios (with confidence intervals) for the key findings were presented in Figure 2 as readers will perhaps be more familiar with odds ratios, and we would like to make the paper accessible to the average reader of scientific literature. Odds ratios (with confidence intervals) for all variables were given in Online Resources 5-6 for those wanting more information. One alternative is to switch Figure 2 for Online Resource 5; we leave this to the Editor's discretion.
-"And the interaction between calendar year and each of volume and location is not given in any table, does this mean it was not even included in the model building in Online Resource 4? That is, it was only included to produce Figure 3 (which incidentally only includes location, not volume)?"
